Cargando…
The coagulopathy in sepsis: significance and implications for treatment
Sepsis related coagulopathy ranges from mild laboratory alterations up to severe disseminated intravascular coagulation (DIC). There is evidence that DIC is involved in the pathogenesis of microvascular dysfunction contributing to organ failure. Additionally, the systemic activation of coagulation,...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
PAGEPress Publications
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3283198/ https://www.ncbi.nlm.nih.gov/pubmed/22355515 http://dx.doi.org/10.4081/pr.2011.e30 |
_version_ | 1782224175335735296 |
---|---|
author | Saracco, Paola Vitale, Pasquale Scolfaro, Carlo Pollio, Berardino Pagliarino, Mauro Timeus, Fabio |
author_facet | Saracco, Paola Vitale, Pasquale Scolfaro, Carlo Pollio, Berardino Pagliarino, Mauro Timeus, Fabio |
author_sort | Saracco, Paola |
collection | PubMed |
description | Sepsis related coagulopathy ranges from mild laboratory alterations up to severe disseminated intravascular coagulation (DIC). There is evidence that DIC is involved in the pathogenesis of microvascular dysfunction contributing to organ failure. Additionally, the systemic activation of coagulation, by consuming platelets and coagulation factors, may cause bleeding. Thrombin generation via the tissue factor/factor VIIa route, contemporary depression of antithrombin and protein C anticoagulant systems, as well as impaired fibrin degradation, due to high circulating levels of PAI-1, contribute to enhanced intravascular fibrin deposition. This deranged coagulopathy is an independent predictor of clinical outcome in patients with severe sepsis. Innovative supportive strategies aiming at the inhibition of coagulation activation should comprise inhibition of tissue factor-mediated activation or restoration of physiological anticoagulant pathways, as the administration of recombinant human activated protein C or concentrate. In spite of some promising initial studies, additional trials are needed to define their clinical effectiveness in adults and children with severe sepsis. |
format | Online Article Text |
id | pubmed-3283198 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | PAGEPress Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-32831982012-02-21 The coagulopathy in sepsis: significance and implications for treatment Saracco, Paola Vitale, Pasquale Scolfaro, Carlo Pollio, Berardino Pagliarino, Mauro Timeus, Fabio Pediatr Rep Review Sepsis related coagulopathy ranges from mild laboratory alterations up to severe disseminated intravascular coagulation (DIC). There is evidence that DIC is involved in the pathogenesis of microvascular dysfunction contributing to organ failure. Additionally, the systemic activation of coagulation, by consuming platelets and coagulation factors, may cause bleeding. Thrombin generation via the tissue factor/factor VIIa route, contemporary depression of antithrombin and protein C anticoagulant systems, as well as impaired fibrin degradation, due to high circulating levels of PAI-1, contribute to enhanced intravascular fibrin deposition. This deranged coagulopathy is an independent predictor of clinical outcome in patients with severe sepsis. Innovative supportive strategies aiming at the inhibition of coagulation activation should comprise inhibition of tissue factor-mediated activation or restoration of physiological anticoagulant pathways, as the administration of recombinant human activated protein C or concentrate. In spite of some promising initial studies, additional trials are needed to define their clinical effectiveness in adults and children with severe sepsis. PAGEPress Publications 2011-12-12 /pmc/articles/PMC3283198/ /pubmed/22355515 http://dx.doi.org/10.4081/pr.2011.e30 Text en ©Copyright P. Saracco et al., 2011 This work is licensed under a Creative Commons Attribution NonCommercial 3.0 License (CC BY-NC 3.0). Licensee PAGEPress, Italy |
spellingShingle | Review Saracco, Paola Vitale, Pasquale Scolfaro, Carlo Pollio, Berardino Pagliarino, Mauro Timeus, Fabio The coagulopathy in sepsis: significance and implications for treatment |
title | The coagulopathy in sepsis: significance and implications for treatment |
title_full | The coagulopathy in sepsis: significance and implications for treatment |
title_fullStr | The coagulopathy in sepsis: significance and implications for treatment |
title_full_unstemmed | The coagulopathy in sepsis: significance and implications for treatment |
title_short | The coagulopathy in sepsis: significance and implications for treatment |
title_sort | coagulopathy in sepsis: significance and implications for treatment |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3283198/ https://www.ncbi.nlm.nih.gov/pubmed/22355515 http://dx.doi.org/10.4081/pr.2011.e30 |
work_keys_str_mv | AT saraccopaola thecoagulopathyinsepsissignificanceandimplicationsfortreatment AT vitalepasquale thecoagulopathyinsepsissignificanceandimplicationsfortreatment AT scolfarocarlo thecoagulopathyinsepsissignificanceandimplicationsfortreatment AT pollioberardino thecoagulopathyinsepsissignificanceandimplicationsfortreatment AT pagliarinomauro thecoagulopathyinsepsissignificanceandimplicationsfortreatment AT timeusfabio thecoagulopathyinsepsissignificanceandimplicationsfortreatment AT saraccopaola coagulopathyinsepsissignificanceandimplicationsfortreatment AT vitalepasquale coagulopathyinsepsissignificanceandimplicationsfortreatment AT scolfarocarlo coagulopathyinsepsissignificanceandimplicationsfortreatment AT pollioberardino coagulopathyinsepsissignificanceandimplicationsfortreatment AT pagliarinomauro coagulopathyinsepsissignificanceandimplicationsfortreatment AT timeusfabio coagulopathyinsepsissignificanceandimplicationsfortreatment |